Delivery Order SPE2DR25D3103-SPE2DR26F9F38
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $8,293.66 to AmerisourceBergen Drug Corp for the supply of Cyclophosphamide 2 GM vials. This competitively awarded, firm fixed-price contract with no set-aside designation was executed on October 17, 2025, with an ultimate completion date of October 20, 2025. The pharmaceutical product will be supplied from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $44,261.94 to AmerisourceBergen Drug Corp for the supply of Cyclophosphamide 2 GM vials. This contract, issued on August 6, 2025, with an ultimate completion date of August 7, 2025, operates under a firm fixed-price arrangement with no set-aside designation, indicating competitive award. The product will be delivered to AmerisourceBergen's location in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters...
- The Defense Logistics Agency awarded a delivery order valued at $1,120.74 to AmerisourceBergen Drug Corp for the supply of Cyclophosphamide 500 mg vials. The contract, awarded on August 8, 2025, with an ultimate completion date of August 11, 2025, operates under firm fixed pricing with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order represents a child contract under...
- The Defense Logistics Agency awarded a delivery order valued at $2,580.30 to AmerisourceBergen Drug Corp for the supply of Cyclophosphamide 1 GM vials, with an ultimate completion date of September 5, 2025. This is a firm fixed-price, non-set-aside contract with performance at the contractor's Conshohocken, Pennsylvania facility. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Cyclophosphamide 2 GM vials under a firm fixed-price contract valued at $4,404.66. The order, issued on November 4, 2025, with an ultimate completion date of November 5, 2025, represents a non-set-aside competitive award. Performance will take place at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order is executed as a child contract under...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $26,197.80 on July 22, 2025, for the supply of Cyclophosphamide 2 GM vials, with an ultimate completion date of July 23, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's Conshohocken, Pennsylvania facility. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Cyclophosphamide 500 mg vials under a firm fixed-price contract valued at $1,226.03. This competitively awarded, non-set-aside delivery order was issued on June 30, 2025, with an ultimate completion date of July 1, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. Cyclophosphamide is a critical chemotherapy agent used in military and federal healthcare...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Cyclophosphamide 500 mg vials, valued at $1,120.74. The award, issued on August 19, 2025, represents a firm fixed-price delivery order under a competitive, non-set-aside procurement. The pharmaceutical product will be delivered to the contractor's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 20, 2025. This delivery order is issued...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation's Corporate Office Division. The $3,735.80 contract is for the delivery of Cyclophosphamide 500 mg vials, a critical pharmaceutical product. The award has an ultimate completion date of August 19, 2024. This order is part of a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at up to $999,999,999 through December 2025, which enables the government to...
- This is a delivery order awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA) Troop Support Medical. The contract is for the supply of 4,565,732,286 units of Cyclophosphamide 2 GM vials, a chemotherapy drug. The $70,284.14 firm-fixed-price contract has an ultimate completion date of September 10, 2024. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued up to...
- SPE2DR25D3103Indefinite Delivery Contract
- SPE2DR25D3103-SPE2DR26F9F38Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $8,809.90 to AmerisourceBergen Drug Corp for the supply of Cyclophosphamide 2 GM vials, with an ultimate completion date of November 14, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and represents a child contract action under AmerisourceBergen's larger federal contract portfolio. The product will be delivered to the company's facility in Conshohocken, Pennsylvania, where the vendor maintains its corporate headquarters and primary operations. This delivery order falls under AmerisourceBergen's Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, designated as SPE2DX and valued at $999,999,999.00 through December 2026. The parent contract serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a broad range of medications, vaccines, and medical supplies to support military healthcare programs worldwide. Cyclophosphamide, a chemotherapy agent, represents one of many specialized pharmaceutical products the company delivers under this vehicle to support Defense Health Agency requirements and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.8k | 11/13/25 |